<- Go Home
MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Market Cap
$79.5M
Volume
642.3K
Cash and Equivalents
$34.4M
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$3.19
52 Week Low
$0.87
Dividend
N/A
Price / Book Value
2.86
Price / Earnings
-1.97
Price / Tangible Book Value
2.86
Enterprise Value
$45.1M
Enterprise Value / EBITDA
N/A
Operating Income
-$25.8M
Return on Equity
148.29%
Return on Assets
-68.33
Cash and Short Term Investments
$34.4M
Debt
N/A
Equity
$27.8M
Revenue
N/A
Unlevered FCF
-$12.1M
Sector
Biotechnology
Category
N/A